Stemline Therapeutics (STML) Stock Rating Lowered by ValuEngine

ValuEngine cut shares of Stemline Therapeutics (NASDAQ:STML) from a strong-buy rating to a buy rating in a research note published on Friday.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright set a $38.00 price target on shares of Stemline Therapeutics and gave the stock a buy rating in a research note on Wednesday, June 6th. Cowen reiterated a buy rating on shares of Stemline Therapeutics in a research note on Thursday, May 10th. Zacks Investment Research downgraded shares of Stemline Therapeutics from a hold rating to a sell rating in a research note on Thursday, February 15th. Wedbush lifted their price target on shares of Stemline Therapeutics from $20.00 to $22.00 and gave the stock an outperform rating in a research note on Tuesday, May 29th. Finally, Roth Capital began coverage on shares of Stemline Therapeutics in a research note on Tuesday, June 12th. They set a buy rating and a $30.00 price target on the stock. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of Buy and an average price target of $30.00.

STML opened at $17.75 on Friday. Stemline Therapeutics has a fifty-two week low of $7.30 and a fifty-two week high of $20.55. The firm has a market cap of $538.88 million and a price-to-earnings ratio of -6.04.



Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.26). Stemline Therapeutics had a negative return on equity of 101.93% and a negative net margin of 4,689.63%. equities analysts forecast that Stemline Therapeutics will post -2.72 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Consonance Capital Management LP lifted its holdings in shares of Stemline Therapeutics by 2,216.9% during the fourth quarter. Consonance Capital Management LP now owns 2,349,792 shares of the biopharmaceutical company’s stock valued at $36,657,000 after acquiring an additional 2,248,372 shares during the period. Citadel Advisors LLC bought a new position in shares of Stemline Therapeutics during the first quarter valued at $8,948,000. venBio Select Advisor LLC bought a new position in shares of Stemline Therapeutics during the first quarter valued at $8,022,000. Nexthera Capital LP bought a new position in shares of Stemline Therapeutics during the first quarter valued at $8,011,000. Finally, Lyon Street Capital LLC lifted its holdings in shares of Stemline Therapeutics by 49.7% during the first quarter. Lyon Street Capital LLC now owns 1,241,293 shares of the biopharmaceutical company’s stock valued at $18,992,000 after acquiring an additional 412,203 shares during the period. Hedge funds and other institutional investors own 66.91% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply